![John Ruesch](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
John Ruesch
Corporate Officer/Principal chez ASTRIA THERAPEUTICS, INC.
Postes actifs de John Ruesch
Sociétés | Poste | Début | Fin |
---|---|---|---|
ASTRIA THERAPEUTICS, INC. | Corporate Officer/Principal | 17/07/2023 | - |
Historique de carrière de John Ruesch
Anciens postes connus de John Ruesch
Sociétés | Poste | Début | Fin |
---|---|---|---|
SURFACE ONCOLOGY, INC. | Corporate Officer/Principal | - | - |
Formation de John Ruesch
Valparaiso University | Undergraduate Degree |
Kellogg School of Management | Masters Business Admin |
Statistiques
Internationale
Etats-Unis | 5 |
Opérationnelle
Corporate Officer/Principal | 2 |
Undergraduate Degree | 1 |
Masters Business Admin | 1 |
Sectorielle
Health Technology | 3 |
Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
ASTRIA THERAPEUTICS, INC. | Health Technology |
Entreprise privées | 1 |
---|---|
Surface Oncology, Inc.
![]() Surface Oncology, Inc. BiotechnologyHealth Technology Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company, which engages in the provision of biological pathways critical to the immunosuppressive tumor microenvironment for the development of next-generation cancer therapies. The firm’s pipeline includes wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). Its pipeline also includes licensed product programs, such as a collaboration with Novartis targeting CD73 (NZV930, Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813, preclinical). The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA. | Health Technology |
- Bourse
- Insiders
- John Ruesch
- Expérience